Profile data is unavailable for this security.
About the company
Shenzhen YHLO Biotech Co Ltd is a China-based company principally engaged in the research and development, manufacture and sales of in-vitro diagnostic equipment and supporting reagents, as well as the agency sales of some non-self-produced medical device products. The Company's products are applied in autoimmunity, reproductive health, diabetes and infectious disease fields. The Company's main products include in-vitro diagnostic instruments and supporting reagents based on chemiluminescence, immunoblotting, enzyme-linked immunoassay, immunofluorescence chromatography and other methodologies. The Company distributes its products in domestic market and to overseas markets.
- Revenue in CNY (TTM)1.90bn
- Net income in CNY288.64m
- Incorporated2008
- Employees1.76k
- LocationShenzhen YHLO Biotech Co LtdNo. 65, Baolong 2nd RoadBaolong Neighbourhood, Longgang DistrictSHENZHEN 518116ChinaCHN
- Phone+86 75 584821649
- Fax+86 75 526473319
- Websitehttps://www.szyhlo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Microport EP MedTech Co Ltd | 383.99m | 35.90m | 10.24bn | 577.00 | 285.13 | 5.91 | -- | 26.66 | 0.0763 | 0.0763 | 0.816 | 3.68 | 0.2081 | 1.30 | 7.04 | 665,493.30 | 1.95 | -- | 2.05 | -- | 57.86 | -- | 9.35 | -- | 13.82 | -- | 0.0109 | -- | 26.46 | -- | 85.17 | -- | -- | -- |
| Vcanbio Cell & Gene Engineering Corp Ltd | 1.59bn | 107.45m | 10.58bn | 2.21k | 96.01 | 2.92 | -- | 6.64 | 0.2354 | 0.2354 | 3.45 | 7.73 | 0.2977 | 1.90 | 2.59 | 721,260.30 | 1.90 | 1.13 | 2.68 | 1.61 | 68.10 | 67.76 | 6.38 | 3.84 | 1.48 | 7.89 | 0.0296 | 0.00 | 2.24 | 3.78 | -5.78 | 12.43 | -7.11 | -- |
| Shenzhen YHLO Biotech Co Ltd | 1.90bn | 288.64m | 10.89bn | 1.76k | 38.00 | 4.10 | -- | 5.73 | 0.5026 | 0.5026 | 3.32 | 4.66 | 0.4842 | 1.07 | 4.58 | 1,081,307.00 | 5.85 | 16.43 | 7.46 | 24.16 | 63.98 | 53.26 | 12.08 | 20.01 | 1.28 | 9.13 | 0.2474 | 30.28 | -48.42 | 23.02 | -64.93 | 56.32 | 28.88 | -- |
| Shinva Medical Instrument Co Ltd | 10.12bn | 692.34m | 11.26bn | 8.21k | 13.13 | 1.50 | -- | 1.11 | 1.41 | 1.41 | 18.31 | 12.34 | 0.6775 | 2.20 | 4.96 | 1,232,589.00 | 4.72 | 4.63 | 9.14 | 10.76 | 25.62 | 24.22 | 6.96 | 6.12 | 0.8303 | -- | 0.1637 | 15.91 | 7.87 | -0.5342 | 30.78 | 95.70 | -5.90 | 61.86 |
| Qingdao Haier Biomedical Co Ltd | 2.24bn | 358.01m | 11.69bn | 2.64k | 32.63 | 2.72 | -- | 5.23 | 1.13 | 1.13 | 7.04 | 13.53 | 0.4018 | 5.12 | 6.38 | 848,473.70 | 6.56 | 11.49 | 8.29 | 15.22 | 47.82 | 49.98 | 16.34 | 25.20 | 2.53 | -- | 0.0316 | 26.53 | -20.36 | 22.07 | -32.41 | 28.94 | 20.64 | -- |
| Beijing Wandong Medical Technolgy Co Ltd | 1.40bn | 184.09m | 12.17bn | 1.06k | 66.07 | 2.57 | -- | 8.67 | 0.262 | 0.262 | 2.00 | 6.74 | 0.2647 | 2.76 | 4.01 | 1,325,746.00 | 3.50 | 5.30 | 3.91 | 6.21 | 38.83 | 45.21 | 13.22 | 16.46 | 9.48 | -- | 0.0179 | 35.82 | 10.30 | 5.32 | 7.51 | 4.22 | -16.66 | 5.39 |
| Shandong Weigao Orthopaedic Devce Co Ltd | 1.28bn | 154.60m | 12.19bn | 2.21k | 79.00 | 3.12 | -- | 9.49 | 0.3858 | 0.3858 | 3.20 | 9.78 | 0.2524 | 0.6714 | 4.03 | 581,131.60 | 3.14 | 10.97 | 3.95 | 13.69 | 62.40 | 77.33 | 12.43 | 27.08 | 3.62 | -- | 0.0096 | 17.90 | -30.55 | 1.17 | -79.36 | -19.11 | -4.31 | -- |
| Shanghai Runda Medical Technology Co Ltd | 8.43bn | 40.27m | 13.18bn | 3.32k | 326.80 | 3.07 | -- | 1.56 | 0.0673 | 0.0673 | 13.61 | 7.17 | 0.5831 | 4.19 | 1.49 | 2,543,990.00 | 1.18 | 4.78 | 3.13 | 12.86 | 25.94 | 27.13 | 2.03 | 6.36 | 1.01 | 3.04 | 0.5609 | 12.43 | -12.84 | 8.93 | -34.58 | 0.8514 | 3.88 | 1.03 |
Data as of Sep 13 2024. Currency figures normalised to Shenzhen YHLO Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
33.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Sep 2024 | 26.60m | 9.94% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 20.81m | 7.77% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2024 | 11.45m | 4.28% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2024 | 5.74m | 2.15% |
| Changsheng Fund Management Co., Ltd.as of 30 Jun 2024 | 5.70m | 2.13% |
| Great Wall Fund Management Co., Ltd.as of 30 Jun 2024 | 4.36m | 1.63% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 3.89m | 1.46% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 3.75m | 1.40% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2024 | 3.50m | 1.31% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 2.68m | 1.00% |
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
